Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Marksans Pharma Ltd Performance

Today's Low
161.15
arrowIcon
Today's High
169.00
52 Wk Low
70.55
arrowIcon
52 Wk High
185.50


Open

165.7

Traded Value (Cr)

17.06

Prev. Close

166.75

Face Value

1

Volume

1023254

Marksans Pharma Ltd Fundamentals

Market Cap
₹ 7474.94 Cr
P/E Ratio (TTM)
23.56
P/B Ratio
3.99
Debt to Equity
0.08
ROE
10.85
EPS (TTM)
7.00
Dividend Yield
0.30 %
Book Value
41.39

Click here to know more about Fundamentals

Marksans Pharma Ltd Financials

Marksans Pharma Ltd Financials

Marksans Pharma Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 43.85 % 43.85 % 43.85 % 43.85 %
Retail 30.91 % 30.81 % 32.12 % 32.36 %
FII 15.57 % 15.56 % 15.07 % 14.91 %
Others 5.44 % 5.96 % 5.81 % 6.09 %
Mutual Funds 4.23 % 3.82 % 3.15 % 2.79 %

Promoters

43.85%

Retail

30.91%

FII

15.57%

Others

5.44%

Mutual Funds

4.23%

Promoters

43.85%

Retail

30.81%

FII

15.56%

Others

5.96%

Mutual Funds

3.82%

Promoters

43.85%

Retail

32.12%

FII

15.07%

Others

5.81%

Mutual Funds

3.15%

Promoters

43.85%

Retail

32.36%

FII

14.91%

Others

6.09%

Mutual Funds

2.79%

Resistance and Support

₹165.63

PIVOT

resistance-arrow
Resistance
First Resistance₹170.117
Second Resistance₹173.483
Third Resistance₹177.967
support-arrow
Support
First Support₹162.267
Second Support₹157.783
Third Support₹154.417

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day415,236452,34445.48
Week994,651518,788157.08
1 Month994,6511,094,590157.08
6 Months246,137,432108,014,17151.22

About Marksans Pharma Ltd

Marksans Pharma Limited is a public limited company incorporated in the year April 16th, 1982. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. The Company on 30th March 2015, issued and allotted 240,06,494 equity shares of Rs1/- each to qualified institutional buyers under QIP for cash at Rs54.67 (including premium) per Equity Share. In accordance to terms of issue, the Directors in their meeting held on 7th February, 2015 decided to redeem entire 13,50,000 7% Redeemable Cumulative Preference Shares of face value Rs100/- per share at par out of profits in tranches before due date of redemption i.e 27th March, 2018. Accordingly, on 7th February 2015, the Directors redeemed 1,00,000 preference shares at par. The Company issued 50,000 Bonds of USD 1,000 each in principal value during the financial year 2015. As on date of report, the Company bought back and extinguished 49,939 Bonds. Of which, only 61 Bonds of USD 1,000 each in principal value (out of total 50,000 Bonds issued) remained outstanding as the same are not traceable During the year 2017, the Company redeemed 1,50,000 preference shares of Rs100/-each at par. Accordingly, issued, subscribed and paid-up preference share capital reduced from 12,50,000 preference shares of Rs100/- each to 11,00,000 preference shares of Rs100/- each with effect from 31st March 2017.

Managing Director

1992

Founded

Mark Saldanha

NSE Symbol

MARKSANS

Marksans Pharma Ltd Management

NameDesignation
Mark SaldanhaChairman & Managing Director
Harshavardhan PanigrahiCompany Sec. & Compli. Officer
Seetharama Raju BuddharajuNon-Exec. & Independent Dir.
Sandra SaldanhaWhole-time Director
Digant Mahesh ParikhNon-Exec. & Independent Dir.
Varddhman Vikramaditya JainWhole-time Director
Abhinna Sundar MohantyNon-Exec. & Independent Dir.
Sunny SharmaDirector
Shailaja VardhanIndependent Director

Events

Dividend Announcement for Marksans Pharma Ltd - May 30, 2023

On May 30, 2023, shareholders are set to receive a dividend payout, with each share entitling its holder to a dividend of 50.0%. This dividend percentage reflec...

Read More

Marksans Pharma Ltd News

Marksans Pharma declare Quarterly Result
On 30 May 2024
Marksans Pharma declines after US FDA issues Form 483 with 5 observations to Goan plant
Marksans Pharma slipped 1.50% to Rs 173.85 after the United States Food and Drug Administration (US FDA) issued 5 observations in Form 483 after inspecting the company’s Goa-based plant.
Marksans Pharma's Goa unit concludes USFDA inspection with observations
Marksans Pharma consolidated net profit rises 31.27% in the December 2023 quarter
Sales rise 22.15% to Rs 586.13 crore
Marksans Pharma jumps after Q3 PAT climbs 34% YoY to Rs 83 cr
Marksans Pharma rallied 8.38% to Rs 159 after the company’s consolidated net profit jumped 33.69% to Rs 83.29 crore in Q3 FY24 as compared with Rs 62.30 crore in Q3 FY23.
Marksans Pharma to declare Quarterly Result
On 13 February 2024
Marksans Pharma receives upgrade in credit ratings
Marksans Pharma consolidated net profit rises 36.36% in the September 2023 quarter
Sales rise 17.38% to Rs 531.24 crore
Marksans Pharma standalone net profit declines 22.22% in the September 2023 quarter
Sales rise 20.21% to Rs 204.67 crore
Marksans arm receives UK MHRA marketing authorisation for Cyanocobalamin 50mg film coated tablet

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 369725.52 Cr
₹ 1,539.30
(-0.11 %)
89.76
Cipla Ltd₹ 116450.58 Cr
₹ 1,482.30
(2.77 %)
31.37
Zydus Lifesciences Ltd₹ 109513.48 Cr
₹ 1,080.65
(-0.71 %)
31.76
Divis Laboratories Ltd₹ 106626.78 Cr
₹ 4,058.55
(1.05 %)
78.20
Dr Reddys Laboratories Ltd₹ 96417.62 Cr
₹ 5,872.75
(1.61 %)
22.21

Marksans Pharma Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Marksans Pharma Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Marksans Pharma Ltd's share price is ₹166.75 as of May 22, 2024 at 03:59 PM

Marksans Pharma Ltd's P/E ratio is 23.56 times as of May 22, 2024 at 03:59 PM.

Marksans Pharma Ltd's most recent financial reports indicate a price-to-book ratio of 3.99, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Marksans Pharma Ltd's market is 7,475 Cr as on May 22, 2024 at 03:59 PM.

The current financial records of Marksans Pharma Ltd show a 10.85% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Marksans Pharma Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

The 52-week high/low price of a Marksans Pharma Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Marksans Pharma Ltd's 52-week high and low as of May 22, 2024 at 03:59 PM are ₹185.5 and ₹185.5 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Marksans Pharma Ltd stands at 43.85%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 15.56% to 15.57%.